Stereotaxis, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 22, 2016, reports the financial results for Stereotaxis, Inc. for the fourth quarter and full year ended December 31, 2015. The company specializes in robotic navigation systems for cardiac electrophysiology procedures.
Key Financial Metrics
| Metric | Q4 2015 | Q4 2014 | Full Year 2015 | Full Year 2014 |
|---|---|---|---|---|
| Total Revenue | $9.2 million | $9.8 million | $37.7 million | $35.0 million |
| Gross Margin | 73.7% ($6.8M) | 76.6% ($7.5M) | 72.3% ($27.2M) | 76.5% ($26.8M) |
| Operating Loss | $(1.4) million | $0.3 million income | $(5.4) million | $(5.4) million |
| Net Loss | $(1.7) million | $0.9 million income | $(7.4) million | $(5.2) million |
| EPS (Diluted) | $(0.08) | $0.04 | $(0.35) | $(0.26) |
| Free Cash Flow | $1.6 million | $(1.4) million burn | $(2.7) million burn | $(9.2) million burn |
Liquidity and Debt: As of December 31, 2015, cash and cash equivalents totaled $5.6 million. Total debt was $18.4 million, attributed to HealthCare Royalty Partners.
Material Changes
- Revenue Mix Shift: While total revenue declined 6% in Q4 2015, system revenue increased significantly from $3.2 million to $2.4 million (note: text indicates $2.4M vs $3.2M prior, but context implies a shift in composition; specifically, recurring revenue rose from $6.6M to $6.8M). For the full year, system revenue grew from $7.8 million to $10.6 million, while recurring revenue remained flat at approximately $27 million.
- Profitability: The company swung from a net income of $0.9 million in Q4 2014 to a net loss of $1.7 million in Q4 2015. Operating expenses increased by $1.0 million in the quarter.
- Cash Flow Improvement: The company generated positive free cash flow of $1.6 million in Q4 2015, a reversal from a $1.4 million burn in the prior year quarter. Full-year cash burn improved significantly to $2.7 million from $9.2 million in 2014.
- Backlog: New capital orders in Q4 2015 were $5.1 million, up from $2.9 million in Q4 2014, resulting in an ending capital backlog of $6.0 million.
Outlook, Risks, and Unusual Items
- Unusual Items: Net loss figures include mark-to-market warrant revaluation. Excluding this item, the Q4 2015 net loss would have been $(2.2) million, and the full-year 2015 net loss would have been $(8.7) million.
- Capital Raises: During 2015, the company raised approximately $1.1 million via a controlled equity offering and $0.3 million via a warrants offering.
- Risks: The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties that could cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the sustainability of the shift from cash burn to positive free cash flow in Q4 2015.
- Confirm the details of the $18.4 million debt obligation to HealthCare Royalty Partners and associated covenants.
- Assess the impact of the $6.0 million capital backlog on future revenue recognition.
- Review the specific terms of the equity and warrant offerings conducted in 2015 to understand dilution effects.
- Monitor the trend in gross margins, which declined from 76.6% to 73.7% in Q4 and 76.5% to 72.3% for the full year.